NASDAQ : CRSP
CRISPR Therapeutics AG — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 54.26 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.97B |
| Enterprise Value | 3.39B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 96.69M |
| Shares Outstanding | 96.69M |
| Shares Change (YoY) | +10.33% |
| Shares Change (QoQ) | +0.48% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 78.70% |
| Float | 96.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 371.26 |
| Forward PS | 61.66 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 2.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 253.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 17.85 |
| Quick Ratio | 17.79 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.09% |
| Return on Assets (ROA) | -14.20% |
| Return on Invested Capital (ROIC) | -325.94% |
| Return on Capital Employed (ROCE) | -21.12% |
| Weighted Average Cost of Capital (WACC) | 12.03% |
| Revenue Per Employee | $34,076 |
| Profits Per Employee | -$1.15M |
| Employee Count | 393 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.03M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.76 |
| 52-Week Price Change | -17.81% |
| 50-Day Moving Average | 54.19 |
| 200-Day Moving Average | 52.88 |
| Relative Strength Index (RSI) | 47.60 |
| Average Volume (20 Days) | 1,528,603 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 16.44M |
| Short Previous Month | 18.68M |
| Short % of Shares Out | 17.00% |
| Short % of Float | 17.09% |
| Short Ratio (days to cover) | 9.18 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 13.39M |
| Gross Profit | -461.80M |
| Operating Income | -531.87M |
| Pretax Income | -448.11M |
| Net Income | -451.14M |
| EBITDA | -513.17M |
| EBIT | -531.87M |
| Loss Per Share | -$4.76 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.36B |
| Total Debt | 783.75M |
| Net Cash | 1.58B |
| Net Cash Per Share | $16.35 |
| Equity (Book Value) | 1.75B |
| Book Value Per Share | 18.07 |
| Working Capital | 2.24B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -369.58M |
| Capital Expenditures | -1.74M |
| Depreciation & Amortization | 18.69M |
| Net Borrowing | 600.00M |
| Free Cash Flow | -371.33M |
| FCF Per Share | -$3.84 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,971.53% |
| Pretax Margin | -3,346.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.33% |
| Shareholder Yield | -10.33% |
| Earnings Yield | -9.26% |
| FCF Yield | -7.47% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $85.63 |
| Price Target Difference | 66.53% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 444.24% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.68 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |